CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of an abstract based on the RELIEVE study. The results from this investigator-led trial will be presented at the 2024 American Burn Association (ABA) annual meeting, scheduled to take place from April 9th-12th in Chicago.
The pRospective, case-controlled Evaluation of oLIceridine for moderate or sEVEre pain in patients with acute burn injuries (RELIEVE) study was led by David Hill, PharmD. from the Firefighters Burn Center in Memphis, TN. This single-center, prospective, case-controlled study received dual IRB approval and included 10 patients with burn injuries who were treated with OLINVYK between April and September 2023.
Patients treated with OLINVYK were compared to a matched historical control group, which included treatment across a range of other IV opioids. The study protocol guided dosing and assessments, with the study team assessing safety and efficacy daily at a minimum.
Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, expressed his anticipation for the upcoming presentation of the study’s findings. He stated, “The results of the RELIEVE study will be reported during the ABA meeting and we are pleased to see additional clinical data in this patient type where new therapeutic options are needed.”
Trevena provided the financial support and study drug for the trial. Dr. Hill, who was independently responsible for the development and submission of the abstract, has previously served as a consultant for Trevena. The upcoming presentation of the RELIEVE study results underscores Trevena’s unwavering commitment to advancing medical knowledge and developing innovative treatment options for patients with central nervous system disorders.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.